QSAR Differential Model for Prediction of SIRT1 Modulation using Monte Carlo Method

Drug Research

Volumn 67, Issue 3, 2017, Pages 156-162

  Kumar, Ashwani ^a   Chauhan, Shilpi ^a  

^a GURU JAMBHESHWAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

N [2 [3 (1 PIPERAZINYLMETHYL)IMIDAZO[2,1 B]THIAZOL 6 YL]PHENYL] 2 QUINOXALINECARBOXAMIDE; RESVERATROL; SIRTUIN 1; SIRT1 PROTEIN, HUMAN;

ARTICLE; CORRELATION COEFFICIENT; MEASUREMENT ACCURACY; MODULATION; MONTE CARLO METHOD; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RANDOMIZATION; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR MODEL; SOFTWARE;

HUMANS; MODELS, MOLECULAR; MONTE CARLO METHOD; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SIRTUIN 1; SOFTWARE;

EID: 85008256409     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0042-119725     Document Type: Article

References (54)

1. Ekwall K. Genome-wide analysis of HDAC function. Trends Genet: 2005; 21 608 615
2. Kumar A., Chauhan S. How much successful are the medicinal chemists in modulation of SIRT1: A critical review. Eur J Med Chem: 2016; 119 45 69
3. Benigni R. Alternatives to the carcinogenicity bioassay for toxicity prediction: are we there yet? Expert Opin Drug Met: 2012; 8 407 417
4. Mor S., Nagoria S., Kumar A. et al. QSAR studies and design of some tetracyclic 1,4-benzothiazines as antimicrobial agents. Drug Res (Stuttg): 2016; 66 436 443
5. Bansal A., Kumar P., Narasimhan B. Synthesis, antimicrobial evaluation and QSAR studies of 2-hydroxy propanoic acid derivatives. Drug Res (Stuttg): 2014; 64 240 245
6. Fernández A., Lombardo A., Rallo R. et al. Quantitative consensus of bioaccumulation models for integrated testing strategies. Expert Opin Drug Metab Toxicol: 2012; 45 51 58
7. CORAL http://www.insilico.eu/coral/ Accessed on May 9, 2016
8. Toropov A. A., Toropova A. P. CORAL software: prediction of carcinogenicity of drugs by means of the Monte Carlo method. Eur J Pharm Sci: 2014; 52 21 25
9. Worachartcheewan A., Nantasenamat C., Isarankura-Na-Ayudhya C. et al. QSAR study of H1N1 neuraminidase inhibitors from influenza A virus. Lett Drug Des Discov: 2014; 11 420 427
10. Martinez JC G., Duchowicz P. R., Estrada M. R. et al. QSAR study and molecular design of open-chain enaminones as anticonvulsant agents. Int J Mol Sci: 2011; 12 9354 9368
11. Masand V. H., Toropov A. A., Toropova A. P. et al. QSAR models for antimalarial activity of 4-aminoquinolines. Curr Comput Aided Drug Des: 2014; 10 75 82
12. Toropova A. P., Toropov A. A., Veselinovic J. B. et al. QSAR models for HEPT derivates as NNRTI inhibitors based on Monte Carlo method. Eur J Med Chem: 2014; 77 298 305
13. Toropov A. A., Toropova A. P., Benfenati E. et al. QSAR models for inhibitors of physiological impact of Escherichia coli that leads to diarrhea. Biochem Biophys Res Commun: 2013; 432 214 225
14. Mullen LM A., Duchowicz P. R., Castro E. A. QSAR treatment on a new class of triphenylmethyl-containing compounds as potent anticancer agents. Chemometr Intell Lab Syst: 2011; 107 269 275
15. Worachartcheewan A., Mandi P., Prachayasittikul V. et al. Large-scale QSAR study of aromatase inhibitors using SMILES-based descriptors. Chemometr Intell Lab Syst: 2014; 138 120 126
16. García J., Duchowicz P. R., Rozas M. F. et al. A comparative QSAR on 1,2,5-thiadiazolidin-3-one 1,1-dioxide compounds as selective inhibitors of human serine proteinases. J Mol Graph Model: 2011; 31 10 19
17. Bemis J. E., Vu C. B., Xie R. et al. Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators. Bioorg Med Chem Lett: 2009; 19 2350 2353
18. Vu C. B., Bemis J. E., Disch J. S. et al. Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators. J Med Chem: 2009; 52 1275 1283
19. Cohen H. Y., Miller C., Bitterman K. J. et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science: 2004; 305 390 392
20. Bemis J. E., Disch J. S., Ng P. Y. et al. Sirtuin modulating compounds. US Patent 2011; 7,893,086
21. Oalmann C., Perni R. B., Disch J. S. et al. Patent Appl; PCT WO 2009/00058348
22. Yang H., Zhang W., Pan H. et al. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-kB activity. PLoS ONE: 2012; 7 1 11
23. +-dependent deacetylase by phenotypic screening. J Biol Chem: 2001; 276 38837 38843
24. Heltweg B., Gatbonton T., Schuler A. D. et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res: 2006; 66 4368 4377
25. +-dependent histone deacetylases (sirtuins). J Med Chem: 2010; 53 1383 1386
26. Lain S., Hollick J. J., Campbell J. et al. Discovery, in vivo activity, and mechanism of action of a small molecule p53 activator. Cancer Cell: 2008; 13 454 463
27. Lara E., Mai A., Calvanese V. et al. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene: 2008; 28 781 791
28. Medda F., Russell RJ M., Higgins M. et al. Novel Cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem: 2009; 52 673 682
29. Napper A. D., Hixon J., McDonagh T. et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem: 2005; 48 8045 8054
30. Nayagam V. M., Wang X., Tan Y. C. et al. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen: 2006; 11 1 8
31. Sanders B. D., Jackson B., Brent M. et al. Identification and characterization of novel sirtuin inhibitor scaffolds. Bioorg Med Chem: 2009; 17 7031 7041
32. Suzuki T., Imai K., Imai E. et al. Design, synthesis, enzyme inhibition, and tumor cell growth inhibition of 2-anilinobenzamide derivatives as SIRT1 inhibitors. Bioorg Med Chem: 2009; 17 5900 5905
33. Suzuki T., Imai K., Nakagawa H. et al. 2-Anilinobenzamides as SIRT inhibitors. Chem Med Chem: 2006; 1 1059 1062
34. Tavares J., Ouaissi A., Lin PK T. et al. Bisnaphthalimidopropyl derivatives as inhibitors of Leishmania SIR2 related protein 1. Chem Med Chem: 2010; 5 140 147
35. +-dependent histone deacetylases (sirtuins). Chem Med Chem: 2007; 2 1419 1431
36. Uciechowska U., Schemies J., Neugebauer R. C. et al. Thiobarbiturates as sirtuin inhibitors: virtual screening, free energy calculations, and biological testing. Chem Med Chem: 2008; 3 1965 1976
37. Choi G., Lee J., Ji J. Y. et al. Discovery of a potent small molecule SIRT1/2 inhibitor with anticancer effects. Int J Oncol: 2013; 43 1205 1211
38. Asaba T., Suzuki T., Ueda R. et al. Inhibition of human sirtuins by in situ generation of an acetylated lysine-ADP-ribose conjugate. J Am Chem Soc: 2009; 131 6989 6996
39. Toropov A. A., Toropova A. P., Benfenati E. et al. The definition of the molecular structure for potential anti-malaria agents by the Monte Carlo method. Struct Chem: 2013; 24 1369 1381
40. OpenBabel version 2.3.2
41. Toropova A. P., Toropov A. A., Benfenati E. et al. CORAL: quantitative structure-activity relationship models for estimating toxicity of organic compounds in rats. J Comput Chem: 2011; 32 2727 2733
42. Benfenati E., Toropov A. A., Toropova A. P. et al. CORAL Software: QSAR for Anticancer Agents. Chem Biol Drug Des: 2011; 77 471 476
43. Cooper J. A., Saracci R., Cole P. Describing the validity of carcinogen screening tests. Br J Cancer: 1979; 39 87 89
44. Toropov A. A., Toropova A. P., Rasulev B. F. et al. CORAL: Binary Classifications (Active/Inactive) for Liver-Related Adverse Effects of Drugs. Curr Drug Saf: 2012; 7 257 261
45. Toropov A. A., Toropova A. P., Benfenati E. et al. CORAL: classification model for predictions of anti-sarcoma activity. Curr Top Med Chem: 2012; 12 2741 2744
46. Toropov A. A., Toropova A. P., Lombardo A. et al. CORAL: the prediction of biodegradation of organic compounds with optimal SMILES-based descriptors. Cent Eur J Chem: 2012; 10 1042 1048
47. Manganelli S., Benfenati E., Manganaro A. et al. New Quantitative Structure-Activity Relationship Models Improve Predictability of Ames Mutagenicity for Aromatic Azo Compounds. Tox Sci: 2016; 1 11
48. Aher R. B., Roy K. First report on exploring classification and regression based QSAR modelling of Plasmodium falciparum glycogen synthase kinase (PfGSK-3) inhibitors. SAR QSAR Environ Res: 2015; 26 959 976
49. Ojha P. K., Roy K. Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection. Chemometr Intell Lab: 2011; 109 146 161
50. Toropov A. A., Toropova A. P., Lombardo A. et al. CORAL: Building up the model for bioconcentration factor and defining it's applicability domain. Eur J Med Chem: 2011; 46 1400 1403
51. Kumar A, Chauhan S. Use of Monte Carlo method for OECD principles guided QSAR modelling of SIRT1 inhibitors. Arch Pharm 2016 (under communication)
52. Cao D., Wang M., Qiu X. et al. Structural basis for allosteric substrate dependent stimulation of SIRT1 activity by resveratrol. Genes Dev: 2015; 29 1316 1325
53. Wu J., Zhang D., Chen L. et al. Discovery and mechanism study of SIRT1 activators that promote the deacetylation of fluorophore-labeled substrate. J Med Chem: 2013; 56 761 780
54. Mahajan S. S., Scian M., Sripathy S. et al. Development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors. J Med Chem: 2014; 57 3283 3294